Factors Associated with Treatment Initiation after Osteoporosis Screening
|
|
- Ruby Craig
- 5 years ago
- Views:
Transcription
1 American Journal of Epidemiology Copyright 2004 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 160, No. 5 Printed in U.S.A. DOI: /aje/kwh245 Factors Associated with Treatment Initiation after Osteoporosis Screening Renee M. Brennan 1, Jean Wactawski-Wende 1,2, Carlos J. Crespo 1, and Jacek Dmochowski 3 1 Department of Social and Preventive Medicine, University at Buffalo, Buffalo, NY. 2 Department of Gynecology/Obstetrics, University at Buffalo, Buffalo, NY. 3 Department of Mathematics, University of North Carolina at Charlotte, Charlotte, NC. Received for publication December 9, 2003; accepted for publication March 24, The prevalence of osteoporosis and factors associated with treatment initiation after detection of osteoporosis were determined for previously unscreened, postmenopausal women. Dual-energy x-ray absorptiometry screening was conducted in as part of an ancillary study of the Buffalo, New York, center of the Women s Health Initiative Observational Study. A total of 945 women were previously unaware of their bone density, although, for 344 (36.4%), osteoporosis was newly detected through screening (T-score 2.5). Of those women, 250 (72.7%) discussed the results with a health care provider, and 140 (56.0%) initiated treatment after doing so. In multivariate logistic regression analyses, factors associated with treatment initiation were T-score (odds ratio (OR) = 0.39 per unit increase, 95% confidence interval (CI): 0.23, 0.67), routine medical care more often than yearly (OR = 2.08, 95% CI: 1.12, 3.86), college education (OR = 2.58, 95% CI: 1.25, 5.31), family income of $50,000 (OR = 2.06, 95% CI: 1.03, 4.14), and discussing screening results with a gynecologist (OR = 3.20, 95% CI: 1.33, 7.67). These findings suggest that many postmenopausal women are unaware of their bone density and could benefit from screening. In this study, approximately half of the women with osteoporosis initiated treatment after screening. Disease severity, medical care frequency, education, income, and physician type predicted treatment initiation. bone density; densitometry; diagnosis; drug therapy; mass screening; osteoporosis, postmenopause; risk factors Abbreviations: CI, confidence interval; DXA, dual-energy x-ray absorptiometry; OR, odds ratio. Osteoporosis is characterized by low bone mass and is a progressive, systemic disease that leads to an increase in bone fragility and susceptibility to fracture (1). Osteoporosis is a major public health threat in the United States; approximately 44 million persons aged 50 years or older, including 30 million women, are affected by the disease (2). The number of persons at risk is increasing as the population ages. While the current economic impact is substantial, management of the disease will require increasing resources in the near future. Detection of osteoporosis is possible at treatable stages of the disease, and early detection and treatment have been shown to decrease associated morbidity and mortality (3). Dual-energy x-ray absorptiometry (DXA) is currently considered the gold standard for measuring bone mineral density and predicting fracture risk (4). Fracture risk is also affected by other factors, such as poor bone quality and a propensity to fall, but bone density is the single best predictor of fracture risk. The US Food and Drug Administration has approved several treatments for the prevention and/or treatment of osteoporosis, including bisphosphonates (alendronate and risedronate), calcitonin, hormone therapy (estrogen alone or in combination with progestin), raloxifene, and teriparatide (5). Inadequate diagnosis and treatment of osteoporosis are a problem (6, 7). Previous studies have shown that providers recommend and women accept drug treatment more often when screening results show an increased risk of fracture (8 12). These studies have focused on the outcomes of a screening test ordered by a physician. Some degree of awareness of the disease and potential interest in treatment are implied when a physician orders a test. The factors associ- Correspondence to Renee M. Brennan, 65 Farber Hall, University at Buffalo, 3435 Main Street, Buffalo, NY ( brennan3@buffalo.edu). 475
2 476 Brennan et al. ated with treatment following screening in an at-risk population not specifically referred by a physician have not been well documented. This study s objectives were to determine the prevalence of osteoporosis in a previously unscreened group of postmenopausal women and, for women newly determined to have osteoporosis at screening, to assess factors associated with drug treatment initiation. MATERIALS AND METHODS The study population comprised participants enrolled in the cross-sectional study, Risk Factors for Osteoporosis and Oral Bone Loss in Postmenopausal Women, conducted from 1997 to 2000 as an ancillary study of the Buffalo, New York, center of the Women s Health Initiative Observational Study. The Women s Health Initiative is an ongoing clinical trial and observational prevention study of postmenopausal women, which is funded by the National Institutes of Health (13). This ancillary study was designed to assess the relation between bone density and periodontal disease. Inclusion criteria were observational study participation and at least six teeth in the mouth. Exclusion factors were known bone disease (other than osteoporosis), known aortic calcification, steroid dependency (use of steroids throughout the past 6 months or longer), and active cancer or cancer chemotherapy. Participants completed several questionnaires that included items on known risk factors for osteoporosis and periodontal disease. Bone densities of the spine, hip, forearm, and total body were measured by DXA (Hologic QDR-4500A; Hologic, Inc., Waltham, Massachusetts), and an oral health examination was completed. Participants were mailed a copy of their DXA results with a summary cover sheet, which included the World Health Organization definitions and values of T-scores for four measured sites (anteroposterior spine, lateral spine, femoral neck, and total forearm). The impact of this DXA screening on study participants was assessed by using a follow-up questionnaire. Participants were asked whether they discussed the DXA results with their health care provider, whether their provider recommended various treatments, whether they initiated any treatment, whether they were complying with treatment, and whether they personally decided to make any changes not recommended by their provider. Participants were mailed the questionnaires at least 1 year after they participated in the study (DXA screening) to allow ample time to discuss their DXA findings with their health care provider. A postagepaid envelope was included to return the completed questionnaires. Questionnaires not returned from the initial mailing were followed up with a second mailing, postcard reminders, and telephone follow-up. This study was approved by the Health Sciences Internal Review Board of the University at Buffalo. Informed consent was obtained for both the Women s Health Initiative study and the Osteoporosis and Oral Bone Loss Study. Data collected from the follow-up questionnaire were combined with existing data from participants records of the Women s Health Initiative Observational Study and the Osteoporosis and Oral Bone Loss Study to form the analytical data set. Since this study aimed to assess the impact of osteoporosis screening in a group of postmenopausal women unaware of their bone density status, participants who reported a previous diagnosis of osteoporosis, previous bone density testing, or ever taking a bone drug other than hormone therapy were excluded from the analyses. Descriptive statistics were computed for demographics and other variables and for outcomes of screening and discussion of results with a health care provider. Univariate logistic regression models were developed to establish factors associated with drug treatment initiation that were further analyzed in multivariate models. Factors assessed included age (years), T-score (lowest of the femoral neck, lateral spine, anteroposterior spine, and total forearm T-scores), body mass index (kilograms per meter squared), race (American Indian/Alaskan Native, Asian/Pacific Islander, Black/African American, Hispanic/Latino, or White), hormone therapy use (never, former, or current), frequency of routine medical care (yearly or less or more often than yearly), fracture history after 40 years of age (yes or no), family history of fracture (yes or no), smoking (ever or never), education (high school or less, college attendance/ graduation, or graduate school attendance/graduation), current employment (yes or no), income (<$50,000 or $50,000), visit date with health care provider ( or after 1998), gender of provider (male or female), length of relationship with provider (years), and specialty of provider (gynecologist or other). The other category for specialty of provider included mainly primary care physicians and internists but also a small number of nurse practitioners, physician s assistants, rheumatologists, endocrinologists, and orthopedists. The multivariate logistic regression modeling attempted to use all factors associated (p < 0.10) with the outcome in univariate models. Stepwise logistic regression, with entry criteria of p < 0.10 and removal criteria of p > 0.05, was used to establish the final multivariate predictive model. The Statistical Package for the Social Sciences (SPSS), version 10.0 for Windows (SPSS, Inc., Chicago, Illinois), was utilized for all analyses. RESULTS Of the 1,952 participants in the Women s Health Initiative Observational Study eligible for the Osteoporosis and Oral Bone Loss Study, 1,468 (75.2 percent) agreed to take part. The remainder were either unable to be contacted (n = 111; 5.7 percent) or uninterested (n = 373; 19.1 percent). The response rate for the Osteoporosis and Oral Bone Loss Study follow-up questionnaire was 95.4 percent (n = 1,400). Of the respondents, 945 reported never being screened or diagnosed with osteoporosis or taking a bone drug other than hormone therapy prior to participation in this study. Baseline characteristics of these 945 participants are presented in table 1. Results of the DXA screening showed that 344 (36.4 percent) women previously unaware of their bone density status were newly determined to have osteoporosis according to World Health Organization criteria. A total of 250 (72.7 percent) of these participants reported discussing results with a health care provider, and 140 (56.0 percent) of those initiated drug treatment (figure 1).
3 Treatment Initiation after Osteoporosis Screening 477 TABLE 1. Baseline characteristics of newly screened postmenopausal women previously unaware of their bone density status (n = 945),* Buffalo, New York, No. or mean (SD ) % Age (years) 72.2 (7.5) DXA T-score value 2.1 (1.2) Body mass index (kg/m 2 ) 27.0 (5.1) Race American Indian/Alaskan Native Asian/Pacific Islander Black/African American Hispanic/Latino White Hormone therapy use Never Former Current Routine medical care (more often than yearly) Fracture history after 40 years of age (yes) Family history of fracture (yes) Smoking (ever) High school or less College attendance/graduation Graduate school attendance/graduation Employment status (employed) Income ( $50,000) Medical insurance (yes) * Race, n = 944; fracture history after 40 years of age, n = 943; family history of fracture, n = 934; education, n = 928; employment status, n = 915; income, n = 894; medical insurance, n = 914. SD, standard deviation. Lowest T-score for the four sites measured by dual-energy x-ray absorptiometry (DXA): femoral neck, lateral spine, anteroposterior spine, and total forearm. Table 2 presents baseline characteristics of the 250 osteoporotic women (T-score 2.5) who discussed their DXA results with their provider. Mean age was 75.5 (standard deviation, 6.6) years, and mean T-score was 3.3 (standard deviation, 0.6). Ninety-eight percent were White, and 25.6 percent were currently using hormone therapy. Most reported college or graduate school education, having medical insurance, and receiving routine medical care at least yearly. Univariate logistic regression results are presented in table 3. Women who initiated treatment were more likely to have a lower T-score (odds ratio (OR) per unit increase = 0.42, 95 percent confidence interval (CI): 0.26, 0.68), routine medical care more often than yearly (OR = 2.01, 95 percent CI: 1.16, 3.50) compared with yearly or less, a college (OR = 1.79, 95 percent CI: 0.96, 3.35) or graduate school (OR = 2.16, 95 percent CI: 1.08, 4.33) education compared with a high school education or less, a total family income of $50,000 or more (OR = 1.80, 95 percent CI: 0.98, 3.33), and discussion of screening results with a gynecologist (OR = 2.85, 95 percent CI: 1.28, 6.30). In multivariate logistic regression analysis (table 4), factors independently associated with treatment initiation were lower T-score (OR per unit increase = 0.39, 95 percent CI: 0.23, 0.67), routine medical care more often than yearly (OR = 2.08, 95 percent CI: 1.12, 3.86) compared with yearly or less, a college education (OR = 2.58, 95 percent CI: 1.25, 5.31) compared with a high school education or less, a total family income of $50,000 or more (OR = 2.06, 95 percent CI: 1.03, 4.14), and discussion of screening results with a gynecologist (OR = 3.20, 95 percent CI: 1.33, 7.67). Because women who were currently receiving hormone therapy could be considered already being treated for osteoporosis, we repeated the analysis, including only those women not using hormone therapy at screening (n = 258). We found that results did not change appreciably. A total of 186 (72.1 percent) women discussed the results with their health care provider, and 103 (55.4 percent) of those women initiated treatment. Women not on hormone therapy who
4 478 Brennan et al. FIGURE 1. Selection of study participants and outcomes of osteoporosis screening, Buffalo, New York, initiated treatment were significantly more likely to have a lower T-score (OR per unit increase = 0.42, 95 percent CI: 0.23, 0.76) and routine medical care more often than yearly (OR = 2.22, 95 percent CI: 1.08, 4.53) compared with yearly or less (table 5). Although not statistically significant, point estimates for higher education, greater income, and gynecologist specialty did not differ appreciably from those presented in table 4. For the variable DXA T-score, the lowest value for the femoral neck, lateral spine, anteroposterior spine, and total forearm was used. These specific T-score values were reported on a summary cover sheet provided to each participant. Women were given a copy of the entire DXA report for each region measured. As such, each woman and her physician had T-score values for each of the sites measured as part of this research study. In a typical clinical setting, lateral spine values are not measured and reported. In fact, the International Society for Clinical Densitometry does not recommend using the lateral spine to diagnose osteoporosis (14). However, since the lateral values were reported, they were included in the analysis. To determine the impact of lateral values on the findings, we repeated the analysis without using lateral spine T-scores in our definition of osteoporosis. Restricting the analysis to the femoral neck, anteroposterior spine, and total forearm resulted in 14 percent fewer participants being defined as having osteoporosis. Regardless, the point estimates (odds ratios) in logistic regression analysis remained appreciably unchanged. Because of a reduced sample size in some instances, confidence intervals widened and resulted in fewer factors reaching statistical significance (data not presented). Similarly, because some providers may have been aware of the National Osteoporosis Foundation guidelines for treatment of osteoporosis, the logistic regression analyses were repeated by restricting them to participants who had a T- score of 2.0 or less. According to National Osteoporosis Foundation guidelines, these participants should be considered for treatment (15). A total of 500 (52.9 percent) participants had T-scores of 2.0 or less, and 357 (71.4 percent) of those women discussed the results with their provider. The logistic regression findings for treatment initiation again did not differ appreciably (data not presented). Finally, the analysis was repeated by restricting it to Caucasian participants only, and our findings did not change (data not presented). DISCUSSION Only one third of study questionnaire respondents had ever been screened for or were determined as being osteoporotic prior to having DXA as part of participation in this research study, but 91 percent of the same group met National Osteoporosis Foundation guidelines for screening (at risk for osteoporosis). The Foundation recommends that all women under the age of 65 years who have one or more additional risk factors for osteoporosis (in addition to being postmenopausal and female) and all women aged 65 years or older, regardless of additional risk factors, should have an osteoporosis screening test (15). Furthermore, for over one third of our study participants who reported never being screened previously, their bone density values met World Health Organization criteria for a diagnosis of osteoporosis (T-score 2.5). Although participants were volunteers from two epidemiologic studies, the prevalence of osteoporosis was similar to that in the Third National Health and Nutrition Examination Survey, a nationally representative sample of the US population (16). Extrapolating our study finding to estimate US population figures, we calculate that 22 million Caucasian women in this age group who meet National Osteoporosis Foundation screening guidelines may be unscreened for osteoporosis and that about 8 million of these women would have undiagnosed disease according to World Health Organization criteria. These calculations are based on a US population estimate of approximately 33 million Caucasian women in the same age range (52 90 years) as that in our study (17). These figures represent conservative population estimates and should be interpreted with caution since our study sample was not a representative, population-based sample. Nevertheless, our results do suggest that a large percentage of women at risk for fracture are currently unaware of their status because of the absence of screening for this condition. Of those women determined at screening to be osteoporotic, 27 percent did not discuss their DXA results with a health care provider. This rate of follow-up is lower than that determined in a previous study by Rubin and Cummings (8), which included a very high percentage of women who received a referral from their physician for
5 Treatment Initiation after Osteoporosis Screening 479 TABLE 2. Baseline characteristics of postmenopausal women previously unaware of their bone density status whose T-score 2.5 at screening and who discussed their results with their health care provider (n = 250),* Buffalo, New York, Total (n = 250, 100%) No. or % mean (SD ) * Total: fracture history after 40 years of age, n = 249; family history of fracture, n = 248; education, n = 249; employment status, n = 244; income, n = 234; medical insurance, n = 244; visit date with provider, n = 245; length of relationship with provider, n = 246. Data were missing on treatment initiation for Black/African-American participants (n = 3). SD, standard deviation. Lowest T-score for the four sites measured by dual-energy x-ray absorptiometry (DXA): femoral neck, lateral spine, anteroposterior spine, and total forearm. Health care provider/physician. screening. This difference in follow-up is likely attributable to the difference in study design; our study involved community-like screening without referral from a physician. Community-based screening tests are effective only if they influence clinical decisions, and an important consideration should be a mechanism to ensure that women discuss screening results with their provider. It is an important public health finding that even within this group of healthy, well-educated, and self-selected women, a large percentage were previously unaware of their bone density status and were newly diagnosed with osteoporosis. Over half of those women determined as having osteoporosis who consulted their health care provider Initiated treatment (n = 140, 56.0%) No. or mean (SD) % Did not initiate treatment (n = 107, 42.8%) No. or mean (SD) Age (years) 75.5 (6.6) 75.8 (6.4) 75.4 (6.9) DXA T-score value 3.3(0.6) 3.4 (0.6) 3.1 (0.5) Body mass index (kg/m 2 ) 25.7 (4.2) 25.3 (4.2) 26.1 (4.3) Race Asian/Pacific Islander Black/African American White Hormone therapy use Never Former Current Routine medical care (more often than yearly) Fracture history after 40 years of age (yes) Family history of fracture (yes) Smoking (ever) High school or less College attendance/graduation Graduate school attendance/graduation Employment status (employed) Income ( $50,000) Medical insurance (yes) Visit date with provider (after 1998) Gender of provider (female) Length of relationship with provider (no. of years) 9.9 (8.8) 9.7 (8.8) 10.3 (8.9) Specialty of provider (gynecologist) after screening initiated treatment, a notable percentage initiating treatment for a disease that may not have been detected without the study DXA screening. However, almost half of the osteoporotic women did not initiate treatment. Decisions regarding initiation of treatment after diagnosis are multifactorial and may be influenced by risk factors for osteoporosis and related fracture other than low bone density. Physician recommendation and patient acceptance of treatment are also important in decision making and may be influenced by the perceived effectiveness of osteoporosis drug treatments or side effects, costs, expected uptake of treatment, or agreement with treatment recommendations. %
6 480 Brennan et al. TABLE 3. Univariate predictors of drug treatment initiation for postmenopausal women previously unaware of their bone density status whose T-score 2.5 at screening and who discussed their results with their health care provider (n = 247),* Buffalo, New York, Unadjusted OR 95% CI p value Age (per year increase) , DXA T-score value (per unit increase) , 0.68 <0.001 Body mass index (kg/m 2 ) (per unit increase) , Race White Asian/Pacific Islander , Hormone therapy use Never * Fracture history after 40 years of age, n = 246; family history of fracture, n = 245; education, n = 246; employment status, n = 241; income, n = 232; visit date with provider, n = 242; length of relationship with provider, n = 243. OR, odds ratio; CI, confidence interval. Lowest T-score for the four sites measured by dual-energy x-ray absorptiometry (DXA): femoral neck, lateral spine, anteroposterior spine, and total forearm. Health care provider/physician. A unique attribute of our study is that we evaluated associations between treatment initiation and characteristics (i.e., gender and specialty) of health care providers. While no significant association was found for gender of the provider, women were over three times as likely to initiate treatment if they consulted a gynecologist compared with other provider specialties. This finding suggests that gynecologists may be more likely to discuss treatment of osteoporosis. Note that the analysis did not account for treatment recommendations of providers that were not initiated by the participant, which may have resulted in underestimation of the response of all specialties of providers to their patients DXA results indicating osteoporosis. It was an interesting finding that, even within a group of women whose T-scores were less than 2.5, women whose scores were lower were more likely to initiate treatment. This finding is consistent with the literature showing that Former , Current , Routine medical care (more often than yearly) , Fracture history after 40 years of age (yes) , Family history of fracture (yes) , Smoking (ever) , High school or less College attendance/graduation , Graduate school attendance/graduation , Employment status (employed) , Income ( $50,000) , Visit date with provider (after 1998) , Gender of provider (female) , Length of relationship with provider (per year increase) , Specialty of provider (gynecologist) , lower T-score, in general, is associated with treatment initiation (8 12). It has been estimated that fracture risk approximately doubles with each standard deviation decrement in bone density compared with optimal mean bone density (18). Therefore, treatment would be expected to increase with worsening T-score and increased fracture risk. Higher level of education and greater income were positively associated with initiation of drug treatment after bone density screening. More-educated women are perhaps more likely to initiate discussions with their health care provider and to have a better understanding of the risks of low bone density. Higher education and income may also be a proxy measure for an increased likelihood of having medical insurance, although only 1 percent of participants in this study did not have medical insurance. No information was available on prescription coverage. A previous study found no association with education (8); however, that study also included
7 Treatment Initiation after Osteoporosis Screening 481 TABLE 4. Multivariate predictors of drug treatment initiation for postmenopausal women previously unaware of their bone density status whose T-score 2.5 at screening and who discussed their results with their health care provider (n = 231), Buffalo, New York, * Odds ratio (OR) adjusted for other variables in the multivariate logistic regression model. CI, confidence interval. Lowest T-score for the four sites measured by dual-energy x-ray absorptiometry (DXA): femoral neck, lateral spine, anteroposterior spine, and total forearm. Health care provider/physician. an overall highly educated group of women. Our study sample had more variation in educational level. Women who reported seeking routine medical care more often than yearly were twice as likely as women who reported less frequent medical care to initiate treatment for osteoporosis. These women are perhaps more health oriented in general and may have more opportunity to discuss their results with their health care provider. Women were surveyed at least 1 year after DXA screening, and the majority reported seeking routine medical care at least yearly. As such, most participants should have had the opportunity to discuss their results with their provider at one of their routine visits. The results showing that higher educational level, greater income, and more frequent routine medical care are associated with treatment initiation indicate that the same groups Adjusted OR* 95% CI p value DXA T-score value (per unit increase) , Routine medical care (more than yearly) , High school or less College attendance/graduation , Graduate school attendance/graduation , Income ( $50,000) , Specialty of provider (gynecologist) , of women who are more likely to utilize the health care system are more likely to discuss results with a health care provider and to initiate treatment after osteoporosis screening. Since screening in a community setting is valuable in reaching at-risk groups who may not otherwise use the health care system, this finding supports continuing challenges in emphasizing both screening and preventive health care for older women. However, this study included a group of women who chose to participate in a health-oriented research study, which may limit generalizability. Women in the general population undergoing osteoporosis screening may be less likely than women in our study to initiate treatment after a diagnosis of osteoporosis. Although hormone therapy use was not found to predict treatment initiation, women who were already receiving TABLE 5. Multivariate predictors of drug treatment initiation for postmenopausal women previously unaware of their bone density status whose T-score 2.5 at screening, who discussed their results with their health care provider, and who were not receiving hormone therapy at screening (n = 174), Buffalo, New York, Adjusted OR* 95% CI p value DXA T-score value (per unit increase) , Routine medical care (more than yearly) , High school or less College attendance/graduation , Graduate school attendance/graduation , Income ( $50,000) , Specialty of provider (gynecologist) , * Odds ratio (OR) adjusted for other variables in the multivariate logistic regression model. CI, confidence interval. Lowest T-score for the four sites measured by dual-energy x-ray absorptiometry (DXA): femoral neck, lateral spine, anteroposterior spine, and total forearm. Health care provider/physician.
8 482 Brennan et al. hormone therapy could be considered to be appropriately treated for osteoporosis, which may have influenced our findings. However, restricting analyses to women not on hormone therapy did not appreciably change our findings. Similarly, race was not found to be a predictor of treatment initiation, but the number of non-white subjects was extremely small. Restriction of analyses to only White subjects did not change our findings. In addition, repeated analyses excluding lateral spine T-scores when determining osteoporotic status and changing the definition of osteoporosis to a T-score of 2.0 or less (National Osteoporosis Foundation treatment guidelines) did not change our findings. This study has a number of strengths, including its similarity to a general population screening. Previous studies have evaluated screening outcomes for women individually referred for screening by their physician (8, 9, 11, 12). Women in our study did not undergo screening because of their individual risk of osteoporosis or physician referral. A further strength of this study was our assessment of treatment initiation at a time when several treatment options had just been approved by the Food and Drug Administration. Prior to 1996, treatment options for osteoporosis were limited largely to hormone therapy. Note that data collection was completed prior to publication of findings of adverse effects of certain types of hormone therapy in the Women s Health Initiative clinical trial (19). Although all races were included in this study, about 98 percent of participants were Caucasian, limiting the generalizability of this study to Caucasian postmenopausal women. Another important consideration is that this analysis did not assess decisions about managing osteoporosis other than prescription drug treatments. Initiation of nonprescription therapies (e.g., calcium and vitamin D) and lifestyle changes (e.g., increased exercise and smoking cessation) were not assessed here but are important in understanding the full influence of screening on change. This is an area for future research. In conclusion, this study showed that many postmenopausal women at risk of osteoporosis remain undiagnosed and untreated. Over one third of those screened had previously undiagnosed osteoporosis. Of those women, less than half subsequently initiated treatment. Women who had lower T-scores, higher educational levels, and greater income and who visited their provider more regularly were more likely to be treated. Additionally, women consulting a gynecologist were more likely to initiate treatment. More effort is needed to increase screening of appropriate persons at risk of osteoporosis and eventual fracture. Additional education on the importance of treatment for women whose bone density is low to prevent fractures should be emphasized to both women and their health care providers. Ultimately, treatment initiation is based on an individualized decision-making process between a woman and her health care provider. Further understanding of the factors that influence decisions to screen for and treat osteoporosis in appropriate persons may be useful in developing strategies to reduce fracture in those at risk. ACKNOWLEDGMENTS This work was supported in part by the following grants and contracts: US Army grants and ; Office of Research on Women s Health and National Heart, Lung, and Blood Institute contract N01WH32122; National Institute of Dental and Craniofacial Research grant R01-DE13505; National Cancer Institute grants 1P120- CA A1 and 1R03-CA ; and National Institute of Environmental Health Sciences grant R01- ES REFERENCES 1. Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement 2000 March 27 29;17(1):1 36. ( odp.od.nih.gov/consensus/cons/111/111_intro.htm). 2. America s bone health: the state of osteoporosis and low bone mass in our nation. Washington, DC: National Osteoporosis Foundation, ( index.htm). 3. Watts NB. Therapies to improve bone mineral density and reduce the risk of fracture: clinical trial results. J Reprod Med 2002;47(1 suppl): Kulak CA, Bilezikian JP. Bone mass measurement in identification of women at risk for osteoporosis. Int J Fertil Womens Med 1999;44: NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285: National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey, Hyattsville, MD: National Center for Health Statistics, (Vital and health statistics, series 1: programs and collection procedures, no. 32) (DHHS publication no. (PHS) ) (GPO no ). 7. Siris E, Miller P, Barrett-Connor E, et al. Design of NORA, the National Osteoporosis Risk Assessment Program. Osteoporos Int 1998;8(suppl 1):S62 S Rubin SM, Cummings SR. Results of bone densitometry affect women s decision about taking measures to prevent fractures. Ann Intern Med 1992;116: Phillipov G, Mos E, Scinto S, et al. Initiation of hormone replacement therapy after diagnosis of osteoporosis by bone densitometry. Osteoporos Int 1997;7: Torgerson DJ, Thomas RE, Campbell MK, et al. Randomized trial of osteoporosis screening. Use of hormone replacement therapy and quality-of-life results. Arch Intern Med 1997;157: Cole RP, Palushock S, Haboubi A. Osteoporosis management: physicians recommendations and women s compliance following osteoporosis testing. Womens Health 1999;29: Marci CD, Viechnicki MB, Greenspan SL. Bone mineral densitometry substantially influences health-related behaviors of postmenopausal women. Calcif Tissue Int 2000;66: Design of the Women s Health Initiative clinical trial and observational study. The Women s Health Initiative Study Group. Control Clin Trials 1998;19: Leib ES, Lewiecki EM, Binkley N, et al. Official positions of the International Society for Clinical Densitometry. J Clin Densitom 2004;7: National Osteoporosis Foundation. Physician s guide to prevention and treatment of osteoporosis. Belle Meade, NJ:
9 Treatment Initiation after Osteoporosis Screening 483 Excerpta Medica Inc, Looker AC, Orwoll ES, Johnston CC, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997;12: Population projections of the United States by age, sex, race, and Hispanic origin: 1995 to Washington, DC: US Census Bureau, ( 1130/). 18. Johnston CC Jr, Slemenda CW. Risk assessment: theoretical considerations. Am J Med 1993;95(5A):2S 5S. 19. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women s Health Initiative randomized controlled trial. JAMA 2002;288:
Summary of the risk management plan by product
Summary of the risk management plan by product 1 Elements for summary tables in the EPAR 1.1 Summary table of Safety concerns Summary of safety concerns Important identified risks Important potential risks
More informationOsteoporosis is estimated to develop in 1 out of 4 women over the age of 50. Influence of bone densitometry results on the treatment of osteoporosis
Influence of bone densitometry results on the treatment of osteoporosis Nicole S. Fitt, * Susan L. Mitchell, * Ann Cranney, Karen Gulenchyn, Max Huang, * Peter Tugwell Abstract Background: Measurement
More informationEffect of Precision Error on T-scores and the Diagnostic Classification of Bone Status
Journal of Clinical Densitometry, vol. 10, no. 3, 239e243, 2007 Ó Copyright 2007 by The International Society for Clinical Densitometry 1094-6950/07/10:239e243/$32.00 DOI: 10.1016/j.jocd.2007.03.002 Original
More informationChallenging the Current Osteoporosis Guidelines. Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA
Challenging the Current Osteoporosis Guidelines Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Whom to screen Which test How to diagnose Whom to treat Benefits
More informationSubmission to the National Institute for Clinical Excellence on
Submission to the National Institute for Clinical Excellence on Strontium ranelate for the prevention of osteoporotic fractures in postmenopausal women with osteoporosis by The Society for Endocrinology
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationOsteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital
Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital What is Osteoporosis? Osteoporosis causes bones to lose density, become
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationDisclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014
Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationQuality and Outcomes Framework Programme NICE cost impact statement July Indicator area: Osteoporosis - fragility fracture
Quality and Outcomes Framework Programme NICE cost impact statement July 2011 Indicator area: Osteoporosis - fragility fracture Indicators NM29: The practice can produce a register of patients: 1. Aged
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationNIH Public Access Author Manuscript Endocr Pract. Author manuscript; available in PMC 2014 May 11.
NIH Public Access Author Manuscript Published in final edited form as: Endocr Pract. 2013 ; 19(5): 780 784. doi:10.4158/ep12416.or. FRAX Prediction Without BMD for Assessment of Osteoporotic Fracture Risk
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationOriginal Article. Ramesh Keerthi Gadam, MD 1 ; Karen Schlauch, PhD 2 ; Kenneth E. Izuora, MD, MBA 1 ABSTRACT
Original Article Ramesh Keerthi Gadam, MD 1 ; Karen Schlauch, PhD 2 ; Kenneth E. Izuora, MD, MBA 1 ABSTRACT Objective: To compare Fracture Risk Assessment Tool (FRAX) calculations with and without bone
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationInterpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm
Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationNew York State County Comparison of Fall-related Hip Fractures of Older Adults and Number of Dual-X-ray Absorptiometry Machines
New York State County Comparison of Fall-related Hip Fractures of Older Adults and Number of Dual-X-ray Absorptiometry Machines Michael Bauer New York State Department of Health Bureau of Occupational
More informationDisparities in Osteoporosis Screening Between At-Risk African-American and White Women
Disparities in Osteoporosis Screening Between At-Risk African-American and White Women Redonda G. Miller, MD, 1 Bimal H. Ashar, MD, 1 Jennifer Cohen, 1 Melissa Camp, 1 Carmen Coombs, 1 Elizabeth Johnson,
More informationScreening for Osteoporosis in Men Aged 70 Years and Older in a Primary Care Setting in the United States
478826JMHXXX10.1177/1557988313478826 American Journal of Men s HealthLim et al. Article Screening for Osteoporosis in Men Aged 70 Years and Older in a Primary Care Setting in the United States American
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationASJ. How Many High Risk Korean Patients with Osteopenia Could Overlook Treatment Eligibility? Asian Spine Journal. Introduction
Asian Spine Journal Asian Spine Clinical Journal Study Asian Spine J 2014;8(6):729-734 High http://dx.doi.org/10.4184/asj.2014.8.6.729 risk patients with osteopenia How Many High Risk Korean Patients with
More informationO. Bruyère M. Fossi B. Zegels L. Leonori M. Hiligsmann A. Neuprez J.-Y. Reginster
DOI 10.1007/s00296-012-2460-y ORIGINAL ARTICLE Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security
More informationThe preferred treatment for osteoporosis
Alternate Options to Hormone Replacement Therapy for Osteoporosis James R. Shoemaker, DO Andrea B. Klemes, DO This presentation, developed from a symposium lecture at the 40th Annual Convention of the
More informationdenosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationBased on review of available data, the Company may consider the use of denosumab (Prolia) for the
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationOral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis
Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis Miriam Silverberg A. Study Purpose and Rationale More than 70% of fractures in people after the age of
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationClinical Practice. Presented by: Internist, Endocrinologist
Clinical Practice Management of Osteoporosis Presented by: SaeedBehradmanesh, h MD Internist, Endocrinologist Iran, Isfahan, Feb. 2017 Definition: A disease characterized by low bone mass and microarchitectural
More informationPrevalence of Osteoporosis p. 262 Consequences of Osteoporosis p. 263 Risk Factors for Osteoporosis p. 264 Attainment of Peak Bone Density p.
Dedication Preface Acknowledgments Continuing Education An Introduction to Conventions in Densitometry p. 1 Densitometry as a Quantitative Measurement Technique p. 2 Accuracy and Precision p. 2 The Skeleton
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationBone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationCan we improve the compliance to prevention treatment after a wrist fracture? Roy Kessous
Can we improve the compliance to prevention treatment after a wrist fracture? Roy Kessous Distal radius fracture in women after menopause is in many cases a first clinical indication for the presence of
More informationComparison of Bone Density of Distal Radius With Hip and Spine Using DXA
ORIGINAL ARTICLE Comparison of Bone Density of Distal Radius With Hip and Spine Using DXA Leila Amiri 1, Azita Kheiltash 2, Shafieh Movassaghi 1, Maryam Moghaddassi 1, and Leila Seddigh 2 1 Rheumatology
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationWellness Coaching for People with Prediabetes
Wellness Coaching for People with Prediabetes PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY Volume 12, E207 NOVEMBER 2015 ORIGINAL RESEARCH Wellness Coaching for People With Prediabetes: A Randomized Encouragement
More informationOsteoporosis. Skeletal System
Osteoporosis Introduction Osteoporosis is a very common bone disease that causes bone to become weak. Bone weakness can lead to fractures of the spine, hip, and wrist from simple falls or even a sneeze
More informationOsteoporosis Physician Performance Measurement Set. October 2006 Coding Reviewed and Updated November 2009
American Academy of Family Physicians/American Academy of Orthopaedic Surgeons/American Association of Clinical Endocrinologists/American College of Rheumatology/The Endocrine Society/Physician Consortium
More informationDEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN
October 2-4, Liverpool, UK EURO SPINE 2013 DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN D. Colangelo, L. A. Nasto, M. Mormando, E.
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationAvailable online at ScienceDirect. Osteoporosis and Sarcopenia 1 (2015) 109e114. Original article
HOSTED BY Available online at www.sciencedirect.com ScienceDirect Osteoporosis and Sarcopenia 1 (2015) 109e114 Original article Localized femoral BMD T-scores according to the fracture site of hip and
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. INJECTABLE OSTEOPOSIS AGENTS SUBJECT Pharmacologic Agents: Bisphosphonates: Boniva IV (ibandronate) Reclast (zoledronic
More informationOsteoporosis Physician Performance Measurement Set. October 2006
American Academy of Family Physicians/American Academy of Orthopaedic Surgeons/American Association of Clinical Endocrinologists/American College of Rheumatology/The Endocrine Society/Physician Consortium
More informationNutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio
Osteoporosis 1 Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio 1) Objectives: a) To understand bone growth and development
More informationsad EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Bone Mineral Density Studies sad EFFECTIVE DATE: 06 07 2011 POLICY LAST UPDATED: 11 06 2018 OVERVIEW Bone density studies can be used to identify individuals with osteoporosis and
More informationDr Tuan V NGUYEN. Mapping Translational Research into Individualised Prognosis of Fracture Risk
Dr Tuan V NGUYEN Bone and Mineral Research Program, Garvan Institute of Medical Research, Sydney NSW Mapping Translational Research into Individualised Prognosis of Fracture Risk From the age of 60, one
More informationAn audit of bone densitometry practice with reference to ISCD, IOF and NOF guidelines
Osteoporos Int (2006) 17: 1111 1115 DOI 10.1007/s00198-006-0101-6 SHORT COMMUNICATION An audit of bone densitometry practice with reference to ISCD, IOF and NOF guidelines R. Baddoura. H. Awada. J. Okais.
More informationBody Mass Index as Predictor of Bone Mineral Density in Postmenopausal Women in India
International Journal of Public Health Science (IJPHS) Vol.3, No.4, December 2014, pp. 276 ~ 280 ISSN: 2252-8806 276 Body Mass Index as Predictor of Bone Mineral Density in Postmenopausal Women in India
More informationPHC4 Issue Brief. Osteoporosis Facts and Figures. November 19, 1997
PHC4 Issue Brief Osteoporosis Facts and Figures November 19, 1997 Background Information: Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue, leading to
More informationBone Mineral Density and Its Associated Factors in Naresuan University Staff
Naresuan University Journal 2005; 13(3): 13-18 13 Bone Mineral Density and Its Associated Factors in Naresuan University Staff Supawitoo Sookpeng *, Patsuree Cheebsumon, Malinee Dhanarun, Thanyavee Pengpan
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationObjectives: What is Osteoporosis 10/8/2015. Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING
Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING TIFFANY PAUL, APN, CNP, CCD Objectives: Review the diagnosis of Osteoporosis Describe the basics of a bone density exam Identify
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Osteoporosis- Do We Need to Think Beyond Bone Mineral Density? Dr Preeti Soni 1, Dr Shipra
More informationScreening for Osteoporosis to Prevent Fractures US Preventive Services Task Force Recommendation Statement
Clinical Review & Education JAMA US Preventive Services Task Force RECOMMENDATION STATEMENT Screening for Osteoporosis to Prevent Fractures US Preventive Services Task Force Recommendation Statement US
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationCosting statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women Resource impact The guidance Denosumab for the prevention of osteoporotic fractures in postmenopausal women
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More informationBONIVA (ibandronate sodium)
BONIVA (ibandronate sodium) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationDXA Best Practices. What is the problem? 9/29/2017. BMD Predicts Fracture Risk. Dual-energy X-ray Absorptiometry: DXA
BMD Predicts Fracture Risk Ten Year Fracture Probability (%) 50 40 30 20 10 Age 80 70 60 50 E. Michael Lewiecki, MD Director, New Mexico Clinical Research & Osteoporosis Center Director, Bone TeleHealth
More informationBuilding Bone Density-Research Issues
Building Bone Density-Research Issues Helping to Regain Bone Density QUESTION 1 What are the symptoms of Osteoporosis? Who is at risk? Symptoms Bone Fractures Osteoporosis 1,500,000 fractures a year Kyphosis
More informationParental Attitudes toward Human Papilloma Virus Vaccine Participation of Adolescent Daughters in a Rural Population
Diversity and Equality in Health and Care (2018) 15(4): 164-168 2018 Insight Medical Publishing Group Research Article Parental Attitudes toward Human Papilloma Virus Vaccine Participation of Adolescent
More informationDXA scanning to diagnose osteoporosis: Do you know what the results mean?
REVIEW CME CREDIT BRADFORD RICHMOND, MD Department of Radiology, The Cleveland Clinic; certification instructor, the International Society for Clinical Densitometry DXA scanning to diagnose osteoporosis:
More informationName of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb ligand
Page 2 of 1765 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Denosumab (AMG 162) Name of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationPredictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA
Osteoporos Int (2010) 21:1427 1436 DOI 10.1007/s00198-009-1079-7 ORIGINAL ARTICLE Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the
More informationINDONESIA CURRENT PROJECTED 2050 COUNTRY OVERVIEW
Indonesia INDONESIA COUNTRY OVERVIEW The Indonesian population is epected to grow by 20% over the net four decades, from 251 million in 2013 to 300 million in 2050. Life epectancy is likely to reach 80
More informationThe Egyptian Journal of Hospital Medicine (January 2018) Vol. 70 (5), Page
The Egyptian Journal of Hospital Medicine (January 2018) Vol. 70 (5), Page 850-854 Awareness of Osteoporosis among Saudi Population in Saudi Arabia Especially Taif governorate Abdulaziz Saleh Alharthi
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: bone_mineral_density_studies 12/1996 9/2017 9/2018 9/2017 Description of Procedure or Service Bone density
More informationOsteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT
Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but
More informationFactors associated with diagnosis and treatment of osteoporosis in older adults
Osteoporos Int (2009) 20:1963 1967 DOI 10.1007/s00198-008-0831-8 SHORT COMMUNICATION Factors associated with diagnosis and treatment of osteoporosis in older adults S. Nayak & M. S. Roberts & S. L. Greenspan
More informationNATIONAL COALITION FOR OSTEOPOROSIS AND RELATED BONE DISEASES
NATIONAL COALITION FOR OSTEOPOROSIS AND RELATED BONE DISEASES Fact Sheet FY 2007 What is the Mission of the Bone Coalition? The National Coalition for Osteoporosis and Related Bone Diseases is dedicated
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationCOPD-Related Musculoskeletal Disease. Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017
COPD-Related Musculoskeletal Disease Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017 A 60-year old man with COPD comes into your office for a routine office visit. He is a former
More informationOverview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence
Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling
More informationPurpose. Methods and Materials
Prevalence of pitfalls in previous dual energy X-ray absorptiometry (DXA) scans according to technical manuals and International Society for Clinical Densitometry. Poster No.: P-0046 Congress: ESSR 2014
More informationPubH 7405: REGRESSION ANALYSIS. Propensity Score
PubH 7405: REGRESSION ANALYSIS Propensity Score INTRODUCTION: There is a growing interest in using observational (or nonrandomized) studies to estimate the effects of treatments on outcomes. In observational
More informationUse of DXA / Bone Density in the Care of Your Patients. Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist
Use of DXA / Bone Density in the Care of Your Patients Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist Important Websites Resources for Clinicians and Patients www.nof.org www.iofbonehealth.org
More informationTwelve-Year Study Update for a Postmarketing Case Series Study of Adult Osteosarcoma and Teriparatide in the US
June 21, 2017 Twelve-Year Study Update for a Postmarketing Case Series Study of Adult Osteosarcoma and Teriparatide in the US David Harris, MPH RTI Health Solutions Co-authors: Kirk Midkiff, MPH, Alicia
More informationBone density scanning and osteoporosis
Bone density scanning and osteoporosis What is osteoporosis? Osteoporosis occurs when the struts which make up the mesh-like structure within bones become thin causing them to become fragile and break
More informationDXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi
DXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi Clinical Utility of Bone Densitometry Diagnosis (DXA)
More informationMedical Policy. MP Vertebral Fracture Assessment With Densitometry
Medical Policy BCBSA Ref. Policy: 6.01.44 Last Review: 09/19/2018 Effective Date: 09/19/2018 Section: Radiology Related Policies 6.01.40 Whole Body Dual X-Ray Absorptiometry to Determine Body Composition
More informationOsteoporosis International. Original Article. Bone Mineral Density and Vertebral Fractures in Men
Osteoporos Int (1999) 10:265 270 ß 1999 International Osteoporosis Foundation and National Osteoporosis Foundation Osteoporosis International Original Article Bone Mineral Density and Vertebral Fractures
More informationEU Osteoporosis Report MALTA
EU Osteoporosis Report 2007-2008 MALTA Overview completed by: Dr Raymond Galea MD, FRCOG, Acc O&G.(Leu) Progress report completed by: Dr Raymond Galea in conjunction with the Strategy and Sustainability
More informationAMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care
AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT SUBJECT: PRESENTED BY: FOR DISTRIBUTION TO: Bone Mineral Density Measurement and the Role of Rheumatologists in the Management of Osteoporosis Committee
More informationThe Relationship between Prevalence of Osteoporosis and Proportion of Daily Protein Intake
Korean J Fam Med. 2013;34:43-48 http://dx.doi.org/10.4082/kjfm.2013.34.1.43 The Relationship between Prevalence of Osteoporosis and Proportion of Daily Protein Intake Original Article Junga Kim, Byungsung
More informationUnderstanding the Development of Osteoporosis and Preventing Fractures: WHO Do We Treat Now?
Understanding the Development of Osteoporosis and Preventing Fractures: WHO Do We Treat Now? Steven M. Petak, MD, JD, FACE, FCLM Texas Institute for Reproductive Medicine And Endocrinology, Houston, Texas
More informationPage 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
More informationOutline. Switching treatment. Evidence from randomized trials. The effects of switching 7/8/2016. When and for whom? Steven Cummings, MD
Outline Switching treatment When and for whom? Steven Cummings, MD Focus on switching from alendronate or risedronate Evidence about the effects of switching on BMD Purposes of switching Symptoms Poor
More informationMeasuring Bone Mineral Density
Measuring Bone Mineral Density Osteoporosis Screening by Pharmacists 9/20/06 Don Downing Institute for Innovative Pharmacy Practice Today s Topics What is osteoporosis? What causes osteoporosis? Screening
More information